Granzyme B PET Imaging of the Innate Immune Response.
PET imaging
granzyme Bhr
inflammation
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
07 Jul 2020
07 Jul 2020
Historique:
received:
20
05
2020
revised:
25
06
2020
accepted:
01
07
2020
entrez:
11
7
2020
pubmed:
11
7
2020
medline:
26
2
2021
Statut:
epublish
Résumé
The human immune system is a complex system which protects against invaders and maintains tissue homeostasis. It is broadly divided into the innate and adaptive branches. Granzyme B is serine protease that plays an important role in both and can serve as a biomarker for cellular activation. Because of this, a granzyme B PET agent (GZP) has recently been developed and has been shown to be able to monitor response to immunotherapy. Here, we evaluated the utility of granzyme B PET imaging to assess the innate immune response. We subcutaneously administered LPS to mice to induce inflammation and performed granzyme B PET imaging after 24 and 120 h. We dissected out tissue in the region of injection and performed granzyme B immunofluorescence (IF) to confirm specificity of the GZP radiotracer. Granzyme B PET imaging demonstrated increased uptake in the region of LPS injection after 24 h, which normalized at 120 h. Granzyme B immunofluorescence showed specific staining in tissue from the 24 h time point compared to the PBS-injected control. These findings support the use of granzyme B PET for imaging innate immunity. In certain clinical contexts, the use of GZP PET imaging may be superior to currently available agents, and we therefore suggest further preclinical studies with the ultimate goal of translation to clinical use.
Identifiants
pubmed: 32646038
pii: molecules25133102
doi: 10.3390/molecules25133102
pmc: PMC7411671
pii:
doi:
Substances chimiques
Lipopolysaccharides
0
Granzymes
EC 3.4.21.-
Gzmb protein, mouse
EC 3.4.21.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Biomed Sci. 2017 Aug 24;24(1):60
pubmed: 28836970
J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S24-32
pubmed: 19932920
Curr Atheroscler Rep. 2012 Oct;14(5):429-37
pubmed: 22872371
EJNMMI Res. 2011 Aug 17;1(1):14
pubmed: 22214258
Nat Rev Immunol. 2015 Jun;15(6):388-400
pubmed: 25998963
PLoS One. 2010 Jan 29;5(1):e8959
pubmed: 20126467
J Transl Med. 2004 Sep 20;2(1):31
pubmed: 15380049
Biol Chem. 2010 Aug;391(8):873-9
pubmed: 20731542
Cell. 1997 Feb 7;88(3):355-65
pubmed: 9039262
Blood. 2004 Feb 1;103(3):1099-104
pubmed: 14512315
Curr Opin Immunol. 2003 Oct;15(5):533-43
pubmed: 14499262
Cancer Res. 2017 May 1;77(9):2318-2327
pubmed: 28461564
J Leukoc Biol. 2010 Feb;87(2):237-43
pubmed: 19915166
Eur J Nucl Med Mol Imaging. 2010 May;37(5):1047
pubmed: 20119695
Lancet. 2001 Jun 2;357(9270):1777-89
pubmed: 11403834
J Immunother Cancer. 2020 May;8(1):
pubmed: 32461343
Adv Exp Med Biol. 2017;1003:3-14
pubmed: 28667551
Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1274-81
pubmed: 25845377
J Invest Dermatol. 2005 Oct;125(4):629-37
pubmed: 16185260
Theranostics. 2013 Jun 24;3(7):448-66
pubmed: 23843893
Curr Opin Immunol. 1995 Feb;7(1):11-6
pubmed: 7539615
Oncotarget. 2017 Jun 9;8(33):54775-54787
pubmed: 28903381
Oncotarget. 2017 Jan 24;8(4):7175-7180
pubmed: 27764780
EJNMMI Res. 2012 Sep 27;2(1):52
pubmed: 23016793
J Clin Invest. 2007 May;117(5):1137-46
pubmed: 17476343
Clin Cancer Res. 2019 Feb 15;25(4):1196-1205
pubmed: 30327313
Cell Death Differ. 2010 Apr;17(4):616-23
pubmed: 20075940